Publications
664 results found
Nicholson AG, Sauter JL, Nowak AK, et al., 2020, EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach, JOURNAL OF THORACIC ONCOLOGY, Vol: 15, Pages: 29-49, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 87
Akyurek LM, Hussein A, Nicholson AG, et al., 2020, Pulmonary manifestations of systemic karyomegaly, RESPIRATORY MEDICINE CASE REPORTS, Vol: 29, ISSN: 2213-0071
- Author Web Link
- Cite
- Citations: 2
Lim E, Begum S, Batchelor T, et al., 2019, OPTIMUM DIAGNOSTIC PATHWAY AND PATHOLOGIC CONFIRMATION RATE OF EARLY STAGE LUNG CANCER: RESULTS FROM VIOLET, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A15-A15, ISSN: 0040-6376
Daniels E, Kadwani O, Molyneaux P, et al., 2019, TEMPORALLY CLOSE PRESENTATION OF PRIMARY LUNG CANCER AND IDIOPATHIC PULMONARY FIBROSIS (IPF): AN ANALYSIS OF INCIDENT IPF CASES FROM 2007-2018, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A122-A122, ISSN: 0040-6376
Zhang YZ, Brambilla C, Molyneaux PL, et al., 2019, IMPACT OF NUMBER OF SAMPLING SITES AND SPECIMEN DIMENSION ON THE PERFORMANCE OF NUCLEAR GRADE AND GROWTH PATTERNS IN PREDICTING SURVIVAL IN EPITHELIOID MALIGNANT PLEURAL MESOTHELIOMA: A SINGLE INSTITUTION REVIEW OF 614 CASES, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A31-A32, ISSN: 0040-6376
Smith J, Chua FJ, Wells AU, et al., 2019, THE SAFETY OF BRONCHOALVEOLAR LAVAGE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS, Winter Meeting of the British-Thoracic-Society, Publisher: BMJ PUBLISHING GROUP, Pages: A91-A92, ISSN: 0040-6376
Hoang LT, Domingo-Sabugo C, Starren ES, et al., 2019, Metabolomic, transcriptomic and genetic integrative analysis reveals important roles of adenosine diphosphate in haemostasis and platelet activation in non-small-cell lung cancer, Molecular Oncology, Vol: 13, Pages: 2406-2421, ISSN: 1574-7891
Lung cancer is the leading cause of cancer‐related deaths in the world. The most prevalent subtype, accounting for 85% of cases, is non‐small‐cell lung cancer (NSCLC). Lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) are the most common subtypes. Despite recent advances in treatment, the low 5‐year survival rate of NSCLC patients (approximately 13%) reflects the lack of early diagnostic biomarkers and incomplete understanding of the underlying disease mechanisms. We hypothesized that integration of metabolomic, transcriptomic and genetic profiles of tumours and matched normal tissues could help to identify important factors and potential therapeutic targets that contribute to tumorigenesis. We integrated omics profiles in tumours and matched adjacent normal tissues of patients with LUSC (N = 20) and LUAD (N = 17) using multiple system biology approaches. We confirmed the presence of previously described metabolic pathways in NSCLC, particularly those mediating the Warburg effect. In addition, through our combined omics analyses we found that metabolites and genes that contribute to haemostasis, angiogenesis, platelet activation and cell proliferation were predominant in both subtypes of NSCLC. The important roles of adenosine diphosphate in promoting cancer metastasis through platelet activation and angiogenesis suggest this metabolite could be a potential therapeutic target.
Chua F, Desai SR, Nicholson AG, et al., 2019, Pleuroparenchymal Fibroelastosis A Review of Clinical, Radiological, and Pathological Characteristics, ANNALS OF THE AMERICAN THORACIC SOCIETY, Vol: 16, Pages: 1351-1359, ISSN: 1546-3222
- Author Web Link
- Cite
- Citations: 76
Stainer A, Rice A, Devaraj A, et al., 2019, Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults, BMC Pulmonary Medicine, Vol: 19, Pages: 1-9, ISSN: 1471-2466
BackgroundDiffuse alveolar haemorrhage (DAH) is characterized by the diffuse accumulation of red blood cells within the alveoli, presence of ground glass opacities and/or consolidation on computed tomography (CT). Aside from identifiable non-immune causes, DAH is classically subdivided into idiopathic (idiopathic pulmonary haemosiderosis, IPH) and autoimmune DAH. Here we describe three cases presenting with recurrent pulmonary haemorrhage, initially classified as IPH, who, several years after first presentation, develop anti myeloperoxidase antibodies (MPO) positivity, emphysema on CT and, in one case, renal involvement.Case presentationPatient 1 was diagnosed with IPH aged 14. Her disease remained poorly controlled despite immunosuppression, although ANCA remained negative over the years. Nineteen years from initial presentation, she developed MPO-ANCA positive antibodies and mild renal impairment. She was treated with Rituximab with good response. From first presentation, the chest CT was consistently characterized by diffuse ground-glass opacities and interlobular septal thickening. Ten years later, cystic opacities consistent with emphysema, with a striking peribronchovascular distribution, developed. Patient 2 was diagnosed with IPH aged 32. He was treated with corticosteroids and methotrexate, with fluctuating response. At 11 years from initial presentation, MPO-ANCA positivity was identified, and emphysema with a peribronchovascular distribution was observed on CT, with subsequent significant increase in extent. Patient 3 was diagnosed with IPH at the age of seven, and had recurrent episodes of haemoptysis of varying degree of severity, treated with intermittent courses of corticosteroids until age 11, when he was intubated due to severe DAH. Eight years after the diagnosis emphysematous changes were noted on CT and MPO-ANCA positivity developed for the first time 11 years after initial diagnosis.ConclusionsWe believe these three cases highlight: 1) th
Tsao M-S, Carbone M, Galateau-Salle F, et al., 2019, Pathologic Considerations and Standardization in Mesothelioma Clinical Trials, JOURNAL OF THORACIC ONCOLOGY, Vol: 14, Pages: 1704-1717, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 8
Courtiol P, Maussion C, Moarii M, et al., 2019, Deep learning-based classification of mesothelioma improves prediction of patient outcome, NATURE MEDICINE, Vol: 25, Pages: 1519-+, ISSN: 1078-8956
- Author Web Link
- Cite
- Citations: 208
Lim E, Batchelor T, Shackcloth M, et al., 2019, Study protocol for VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a UK multicentre randomised controlled trial with an internal pilot (the VIOLET study), BMJ OPEN, Vol: 9, ISSN: 2044-6055
- Author Web Link
- Cite
- Citations: 40
Spiro SG, Shah PL, Rintoul RC, et al., 2019, Sequential screening for lung cancer in a high-risk group: randomised controlled trial, European Respiratory Journal, Vol: 54, ISSN: 0903-1936
BACKGROUND: Low-dose computed tomography (LDCT) screening detects early-stage lung cancer and reduces mortality. We proposed a sequential approach targeted to a high-risk group as a potentially efficient screening strategy. METHODS: LungSEARCH was a national multicentre randomised trial. Current/ex-smokers with mild/moderate chronic obstructive pulmonary disease (COPD) were allocated (1:1) to have 5 years surveillance or not. Screened participants provided annual sputum samples for cytology and cytometry, and if abnormal were offered annual LDCT and autofluorescence bronchoscopy (AFB). Those with normal sputum provided annual samples. The primary end-point was the percentage of lung cancers diagnosed at stage I/II (nonsmall cell) or limited disease (small cell). RESULTS: 1568 participants were randomised during 2007-2011 from 10 UK centres. 85.2% of those screened provided an adequate baseline sputum sample. There were 42 lung cancers among 785 screened individuals and 36 lung cancers among 783 controls. 54.8% (23 out of 42) of screened individuals versus 45.2% (14 out of 31) of controls with known staging were diagnosed with early-stage disease (one-sided p=0.24). Relative risk was 1.21 (95% CI 0.75-1.95) or 0.82 (95% CI 0.52-1.31) for early-stage or advanced cancers, respectively. Overall sensitivity for sputum (in those randomised to surveillance) was low (40.5%) with a cumulative false-positive rate (FPR) of 32.8%. 55% of cancers had normal sputum results throughout. Among sputum-positive individuals who had AFB, sensitivity was 45.5% and cumulative FPR was 39.5%; the corresponding measures for those who had LDCT were 100% and 16.1%, respectively. CONCLUSIONS: Our sequential strategy, using sputum cytology/cytometry to select high-risk individuals for AFB and LDCT, did not lead to a clear stage shift and did not improve the efficiency of lung cancer screening.
Barnett J, Pulzato I, Wilson R, et al., 2019, Perinodular Vascularity Distinguishes Benign Intrapulmonary Lymph Nodes From Lung Cancer on Computed Tomography, JOURNAL OF THORACIC IMAGING, Vol: 34, Pages: 326-328, ISSN: 0883-5993
- Author Web Link
- Cite
- Citations: 7
Lloyd KL, Rice A, Finch J, et al., 2019, Pulmonary Botryomycosis: A Mimicker of Malignancy, 12th Joint Meeting of the British-Division-of-the-International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland (Leeds Pathology), Publisher: WILEY, Pages: S19-S19, ISSN: 0022-3417
Nicholson AG, 2019, Update on Lung Cancer Staging, 12th Joint Meeting of the British-Division-of-the-International-Academy-of-Pathology and the Pathological-Society-of-Great-Britain-and-Ireland (Leeds Pathology), Publisher: WILEY, Pages: S7-S7, ISSN: 0022-3417
Jacob J, Owens CM, Brody AS, et al., 2019, Evaluation of inter-observer variation for computed tomography identification of childhood interstitial lung disease, International Conference of the American-Thoracic-Society, Publisher: EUROPEAN RESPIRATORY SOC JOURNALS LTD, ISSN: 1073-449X
- Author Web Link
- Cite
- Citations: 2
Jaeger VK, Lebrecht D, Nicholson AG, et al., 2019, Mitochondrial DNA mutations and respiratory chain dysfunction in idiopathic and connective tissue disease-related lung fibrosis, SCIENTIFIC REPORTS, Vol: 9, ISSN: 2045-2322
- Author Web Link
- Cite
- Citations: 22
Januszewski A, Zhang YZ, Chang W-C, et al., 2019, Impact of MET variants on PD-L1 expression in pleomorphic lung carcinoma, European Lung Cancer Congress (ELCC), Publisher: OXFORD UNIV PRESS, Pages: 1-1, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 2
Brambilla C, Rice A, Nicholson AG, 2019, Histology of Pulmonary and Bronchiolar Disorders in Connective Tissue Diseases, SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, Vol: 40, Pages: 147-158, ISSN: 1069-3424
- Author Web Link
- Cite
- Citations: 2
Taylor BA, Hind M, Rice A, et al., 2019, Investigating the Molecular Mechanisms of Congenital Pulmonary Airway Malformation (CPAM), 211th Meeting of the Pathological-Society-of-Great-Britain-and-Ireland, Publisher: WILEY, Pages: S11-S11, ISSN: 0022-3417
Bush A, Griese M, Seidl E, et al., 2019, Early onset children's interstitial lung diseases: Discrete entities or manifestations of pulmonary dysmaturity?, PAEDIATRIC RESPIRATORY REVIEWS, Vol: 30, Pages: 65-71, ISSN: 1526-0542
- Author Web Link
- Cite
- Citations: 27
Rosenthal R, Cadieux EL, Salgado R, et al., 2019, Neoantigen-directed immune escape in lung cancer evolution, NATURE, Vol: 567, Pages: 479-+, ISSN: 0028-0836
- Author Web Link
- Cite
- Citations: 483
Wells AU, Brown KK, Flaherty KR, et al., 2019, Pulmonary fibrosis: "idiopathic" is not "cryptogenic", EUROPEAN RESPIRATORY JOURNAL, Vol: 53, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 1
Yatabe Y, Dacic S, Borczuk AC, et al., 2019, Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer, JOURNAL OF THORACIC ONCOLOGY, Vol: 14, Pages: 377-407, ISSN: 1556-0864
- Author Web Link
- Cite
- Citations: 154
Wells AU, Brown KK, Flaherty KR, et al., 2019, Untitled, EUROPEAN RESPIRATORY JOURNAL, Vol: 53, ISSN: 0903-1936
- Author Web Link
- Cite
- Citations: 7
Januszewski A, Chang W, Zhang Y, et al., 2019, Intratumoral heterogeneity in PD-L1 expression in pleomorphic lung carcinoma: implications for management of stage III disease, British Thoracic Oncology Group, Publisher: Elsevier, ISSN: 0169-5002
Lloyd KL, Rice A, Robertus JL, et al., 2019, National Optimal Lung Cancer Pathway implementation: can pathologists comply with turnaround times?, Publisher: ELSEVIER IRELAND LTD, Pages: S3-S4, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 1
Kumar N, Alrifai D, Kolluria KK, et al., 2019, Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma, LUNG CANCER, Vol: 127, Pages: 164-166, ISSN: 0169-5002
- Author Web Link
- Cite
- Citations: 8
Barnett J, Pulzato I, Padley S, et al., 2019, Radiological-pathological correlation of negative CT biopsy results enables high negative predictive value for thoracic malignancy, Publisher: ELSEVIER IRELAND LTD, Pages: S16-S16, ISSN: 0169-5002
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.